Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Google Disrupts Major Residential Proxy Network IPIDEA 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
LOS ANGELES, May 23, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (Nasdaq:ITCI) concerning possible violations of federal securities laws between August 12, 2014 and April 28, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The Complaint states that, throughout the Class Period, Intra-Cellular made false and/or misleading statements and/or failed to disclose: that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; that these findings posed an additional safety concern regarding lumateperone; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.
On August 4, 2016, Intra-Cellular’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients. When this information was released, Intra-Cellular’s stock price decreased materially, which harmed investors according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
